Trials / Terminated
TerminatedNCT06312657
Behavioral Effects of Drugs Inpatient 44 Neurobehavioral Mechanisms of Opioid Choice
Behavioral Effects of Drugs Inpatient 44: Neurobehavioral Mechanisms of Opioid Choice
- Status
- Terminated
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Joshua A. Lile, Ph.D. · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this protocol is to use probabilistic choice tasks to determine the impact of withdrawal and drug cues on decision-making in individuals with opioid use disorder and physical opioid dependence.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Drug Cue | Individualized drug cues paired with choice options reinforced by $0.25 |
| BEHAVIORAL | Money | Two money values will be tested ($0.25 and $4.00) |
| DRUG | Withdrawal | Participants will be maintained on an opioid agonist. Placebo will be substituted to produce mild-to-moderate withdrawal. |
| DRUG | Remifentanil | IV remifentanil will be made available as one of the choice options in some sessions. |
Timeline
- Start date
- 2023-03-01
- Primary completion
- 2025-03-28
- Completion
- 2025-03-28
- First posted
- 2024-03-15
- Last updated
- 2026-03-30
- Results posted
- 2026-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06312657. Inclusion in this directory is not an endorsement.